Search hospitals > Tennessee > Germantown
Charles Retina Institute
Claim this profileGermantown, Tennessee 38138
Global Leader in Age-Related Macular Degeneration
Global Leader in Macular Edema
Conducts research for Swelling
Conducts research for Diabetic Macular Edema
Conducts research for Atrophy
43 reported clinical trials
2 medical researchers
Summary
Charles Retina Institute is a medical facility located in Germantown, Tennessee. This center is recognized for care of Age-Related Macular Degeneration, Macular Edema, Swelling, Diabetic Macular Edema, Atrophy and other specialties. Charles Retina Institute is involved with conducting 43 clinical trials across 22 conditions. There are 2 research doctors associated with this hospital, such as Stephen Huddleston, MD and Stephan Huddleston, MD.Area of expertise
1Age-Related Macular Degeneration
Global LeaderStage I
Stage II
CFI positive
2Macular Edema
Global LeaderTop PIs
Stephen Huddleston, MDUniversity of Minnesota2 years of reported clinical research
Studies Lung Transplant
Studies Age-Related Macular Degeneration
2 reported clinical trials
3 drugs studied
Stephan Huddleston, MDCharles Retina Institute3 years of reported clinical research
Studies Retinal Disease
Studies Diabetic Retinopathy
1 reported clinical trial
1 drug studied
Clinical Trials running at Charles Retina Institute
Age-Related Macular Degeneration
Macular Edema
Swelling
Diabetic Macular Edema
Convergence Insufficiency
Diabetic Retinopathy
Cancer
Retinal Vein Occlusion
Retinal Disease
Atrophy
RGX-314 Gene Therapy
for Age-Related Macular Degeneration
This trial is testing a new one-time gene therapy called RGX-314 for patients with wet AMD. The goal is to reduce the need for regular treatments by helping the eye produce its own protective proteins. This could make treatment easier and more effective for patients.
Recruiting2 awards Phase 32 criteria
PDS Implant with Ranibizumab
for Age-Related Macular Degeneration
This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in patients with neovascular age-related macular degeneration (nAMD) who have either completed Phase II Study GX28228 (Ladder), Phase III Study GR40548 (Archway), Phase IIIb Study WR42221 (Velodrome), or completed Week 24 visit in Study WR42221 but were not eligible to be randomized in WR42221.
Recruiting2 awards Phase 33 criteria
KHK4951
for Age-Related Macular Degeneration
This trial is testing special eye drops called KHK4951 to help people with a vision problem known as nAMD. The drops aim to improve vision by addressing abnormal blood vessels in the eye.
Recruiting1 award Phase 24 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Charles Retina Institute?
Charles Retina Institute is a medical facility located in Germantown, Tennessee. This center is recognized for care of Age-Related Macular Degeneration, Macular Edema, Swelling, Diabetic Macular Edema, Atrophy and other specialties. Charles Retina Institute is involved with conducting 43 clinical trials across 22 conditions. There are 2 research doctors associated with this hospital, such as Stephen Huddleston, MD and Stephan Huddleston, MD.